AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy-Reference-Cited by-同舟云学术

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Published:2019-04-18 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Bertran-Alamillo Jordi^ORCID,Cattan Valérie,Schoumacher Marie^ORCID,Codony-Servat Jordi,Giménez-Capitán Ana,Cantero Frédérique,Burbridge Mike,Rodríguez Sonia,Teixidó Cristina,Roman Ruth,Castellví Josep^ORCID,García-Román Silvia,Codony-Servat Carles,Viteri Santiago,Cardona Andrés-Felipe,Karachaliou Niki,Rosell Rafael,Molina-Vila Miguel-Angel

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-09734-5.pdf

Reference50 articles.

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).

2. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).

3. Huang, S. F. et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195–8203 (2004).

4. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).

5. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RACGAP1 is a pivotal gene in lung adenocarcinoma-associated membranous nephropathy: Based on comprehensive bioinformatics analysis and machine learning;International Immunopharmacology;2024-09

2. A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer;Cell Chemical Biology;2024-09

3. AURKB promotes immunogenicity and immune infiltration in clear cell renal cell carcinoma;Discover Oncology;2024-07-16

4. AURKB promotes colorectal cancer progression by triggering the phosphorylation of histone H3 at serine 10 to activate CCNE1 expression;Aging;2024-05-06

5. Abstract 4668: Characterization of fourth-generation EGFR inhibitors in binding experiments with C797S mutant EGFR and cell-based assays with osimertinib-resistant non-small cell lung cancer cell lines;Cancer Research;2024-03-22